Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Ministry of Science...

    Ministry of Science and Technology invites Concept Proposals for CAR T Cell therapy

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-03-09T12:17:24+05:30  |  Updated On 9 March 2020 6:47 AM GMT
    Ministry of Science and Technology invites Concept Proposals for CAR T Cell therapy

    Delhi: Through a recent notice, Ministry of Science and Technology has invited Concept Proposals on approach to developing CAR T Cell therapy at an affordable price in India. The last date for the submission of Concept Proposal is 15th March 2020.

    The proposal should be submitted in the prescribed format (4 hard copies) to the following address i.e, Dr Niloo Srivastava, Scientist 'E', Department of Biotechnology, Block-2, Room No.621, 6th floor, CGO Complex, Lodhi Road, New Delhi – 110003 along with a soft copy (both word and pdf format) to be emailed to nsrivastava.dbt@nic.in and manoj.kr09@gov.in.

    CAR-T cell-based therapy has emerged as a breakthrough in cancer treatment. It is a type of treatment in which a patient's T cells are changed in the laboratory enabling them to specifically attack cancer cells and these cells are then infused back into the patient's body. Clinical trials conducted globally have shown promising results in endstage patients especially in patients suffering from Acute Lymphocytic Leukemia.

    Though this technology has a remarkable therapeutic potential for cancer patients, at present this technology is very expensive and not available in India. The challenge, therefore, is to develop this technology in a cost-effective manner and make it available for the patients.

    The goal of this Call is to support milestone-driven multi-institutional/multi-investigator proposals focused on developing CAR-T technology in India. Accordingly Request for Concept Proposals are invited on "Approach to develop CAR T Cell therapy at an affordable price in India" for consideration under the Stem Cells & Regenerative Medicine Programme of the Department. Applications are expected to have defined Milestones and Timelines detailing how the project will move forward with identified deliverables and expected outcomes.

    The focus of the Concept proposal may be on the following, but not limited to:

    1. Basic, early and late translational research studies to develop CAR-T technology in India and also to improve the existing CAR-T cell therapy by exploring new Antigen targets and to expand the CAR T cell therapy for other haematological malignancies and solid tumours.

    2. Development of clinical-grade plasmids/vectors for gene transfer

    https://pubads.g.doubleclick.net/gampad/ads?iu=/21687779244/clinicalkey_video_ad&description_url=[placeholder]&tfcd=0&npa=0&sz=640x480&gdfp_req=1&output=vast&unviewed_position_start=1&env=vp&impl=s&correlator=

    3. Pre-clinical studies and Clinical trials for CAR-T technology

    4. Mitigating possible adverse events, both short and long term for eg., specific modifications in CAR constructs to reduce the post-transplantation incidences of life-threatening cytokine release syndrome (CRS) and neurotoxicity.

    5. Methods to scale-up the production of CAR T cells in an efficient, and effective manner.

    Collaborative proposals may be submitted by public and private universities, colleges, Institutes, non-profit organizations (recognized by DSIR as a Scientific and Industrial Research Organization (SIRO))

    1. The Academic centres if not a medical institute must be linked with a medical centre/hospital preferably within the same city so that patient samples could be easily obtained for the generation of CAR T cells.

    2. These centres/institutes/hospitals should have well-defined teams of basic scientists and clinicians. Basic science team should have a strong background in the areas of molecular biology, cell biology and immunology, whereas the clinical team should have expertise in the management of bone marrow transplant patients and a track record of performing clinical trials.

    3. Existing GMP facility at one of these centres/institutes for manufacturing of CAR - T cells.

    4. All Concept proposals must adhere to statutory regulatory requirements.

    For any queries, contact Dr Manoj Kumar, Scientist-C, Email-manoj.kr09@gov.in / Dr Niloo Srivastava, Scientist-E, Email- nsrivastava.dbt@nic.in

    The ministry has also issued Performa for the same

    1.(i) Project Title:

    (ii) Specific Area of your proposal:

    (iii) Name of the Coordinating institution:

    (iv) Details of Partnering institutions:

    (iv) Names(s) of the Investigator(s),

    (v) Institute address, Contact numbers, emails etc.

    2. Indicate the category of domain expertise and potential of each PIs (Basic and/or clinical research). Multifaceted and multi-institutional collaborations encouraged.

    3. Scientific Hypothesis and key questions to be addressed and Primary Objectives (100 words)

    4. Detailed work plan i.e., how will you test the hypothesis/approach towards the development of technology and solutions? (500 Words)

    5. What is the novelty in your approach?

    6. Feasibility of doing the study in your present institution/workplace:

    7. Tentative budget (under the headings Non-recurring/Manpower/Recurring).

    8. List 4-6 statements on expected deliverables (a) study outcomes (or) translational outcomes.

    9. Professional Experiences and Training relevant to the project

    10. The CV of the investigators as per format (Annexure I).

    11. Any other highlights

    For the full details click on the following link:

    PDF Link: https://business.medicaldialogues.in/pdf_upload/pdf_upload-125180.pdf

    car-t acute-lymphocytic-leukemia cart therapy 

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X